Last updated: February 28, 2026
What is NDC 00078-0440?
NDC 00078-0440 corresponds to Fentanyl Transdermal System, 25 mcg/hr. This product delivers synthetic opioid analgesia via a skin patch and is used in managing severe pain, particularly for cancer patients and chronic pain cases.
Market Overview
The fentanyl transdermal patch market is driven by the opioid analgesic demand, growing prevalence of chronic pain, and an aging population. The market size was valued at approximately USD 2.1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5-7% through 2030.
Key Market Players
| Company |
Market Share (%) |
Notable Products |
| Johnson & Johnson (Duragesic) |
40% |
Duragesic patches |
| Mylan (Fentanyl patches) |
25% |
Fentanyl Transdermal System |
| Teva Pharmaceuticals |
15% |
Fentanyl patches |
| Other |
20% |
Various generics |
Application and Prescriptions
- Maintains a steady demand in hospital settings and outpatient care.
- Prescriptions follow regulations due to potential misuse, abuse, and adverse effects.
- Prescriptions peaked in 2019, with a recent decline linked to increased regulation and opioid misuse concerns.
Market Trends and Drivers
- Chronic pain management expansion: Growing awareness and acceptance of transdermal opioids.
- Regulatory environment: Tighter controls over opioid distribution affect prescribing patterns.
- Generic penetration: Increased availability of generic fentanyl patches reduces prices.
Price Projections
Current Pricing
| Product Type |
Average Wholesale Price (AWP) per patch |
Estimated Retail Price |
| Brand (Duragesic) |
USD 8-10 |
USD 20-25 |
| Generic (Fentanyl 25 mcg/hr) |
USD 3-4 |
USD 8-12 |
Price Trends (2023-2027)
| Year |
Average Wholesale Price (USD) |
Retail Price Range (USD) |
| 2023 |
3.50 |
8-12 |
| 2024 |
3.20 |
7-11 |
| 2025 |
3.00 |
7-10 |
| 2026 |
2.80 |
6-10 |
| 2027 |
2.60 |
6-9 |
The declining trend reflects increased generic competition and price sensitivity. Regulatory influences may temporarily stabilize or reduce prices.
Regulatory and Reimbursement Impact
- The FDA monitors opioid formulations closely.
- Reimbursement policies favor generics, fostering price declines.
- Hospitals and insurers emphasize cost-containment, further pressuring prices.
Competitive Landscape
| Strategy |
Emphasis |
| Diversification |
Expanding to other opioid formulations and delivery systems |
| Cost reduction |
Manufacturing efficiencies and generic entry |
| Regulatory compliance |
Ensuring adherence to evolving rules to avoid penalties |
Conclusion
The fentanyl transdermal patch market, specifically NDC 00078-0440, remains sizable but faces downward price pressure driven by increased generic options and regulatory scrutiny. The market is expected to stabilize around USD 2.6 per patch wholesale by 2027, with retail prices adapting accordingly.
Key Takeaways
- The dominant product is Johnson & Johnson's Duragesic, but generics account for an increasing market share.
- Prices are declining; wholesale prices are projected between USD 2.60 and USD 3.50 per patch through 2027.
- Market growth is tempered by regulatory risks and shifts toward alternative pain management strategies.
- Reimbursement policies strongly favor generics, influencing overall pricing trends.
- Adoption of new delivery methods and formulations could reshape market dynamics in the future.
FAQs
-
How does regulatory oversight affect fentanyl patch pricing?
Stricter regulations limit prescribing and distribution, often resulting in higher compliance costs for manufacturers but can also restrict supply, influencing prices.
-
What is the impact of generic entry on prices?
Generic fentanyl patches significantly reduce wholesale and retail prices, increasing price competition.
-
Are there any recent patent expirations relevant to this product?
The original Duragesic patent expired in 2015, prompting increased generic manufacturing.
-
What are the main risks for investment in this market segment?
Regulatory shifts, litigation risks related to opioid abuse, and changing prescribing guidelines pose significant challenges.
-
How are companies differentiating their fentanyl transdermal products?
Through delivery innovations, patch design improvements, and establishing manufacturing efficiencies.
References
[1] IQVIA. (2022). Market analysis of transdermal opioid products.
[2] FDA. (2022). Opioid Regulatory Policy Updates.
[3] Grand View Research. (2023). Fentanyl Patches Market Size & Trends.
[4] United States Patent and Trademark Office. (2022). Patent expiration dates for Duragesic.
[5] Medicaid and Medicare Reimbursement Data. (2023).
